Search tips
Search criteria 


Logo of jcinvestThe Journal of Clinical InvestigationCurrent IssueArchiveSubscriptionAbout the Journal
J Clin Invest. 1980 March; 65(3): 746–753.
PMCID: PMC371418

Stereoselective Interaction of Phenylbutazone with [12C/13C]Warfarin Pseudoracemates in Man


To evaluate the interaction of phenylbutazone with racemic warfarin or R,S-(±)-warfarin in man, S-(−)-warfarin or levowarfarin was synthesized with 13C label in the 2-position of the coumarin nucleus and added to [12C]R(+)-warfarin or dextrowarfarin to form a [12C/13C]pseudoracemate of warfarin. In six normal human subjects, a single oral dose of this “cold labeled” pseudoracemate, 1.5 mg/kg body weight, was administered with and without a daily dosage of phenylbutazone, 300 mg orally, beginning 3 d before the warfarin dose and continuing throughout the hypoprothrombinemia. Plasma samples were obtained daily and analyzed for warfarin content and for one-stage prothrombin activity. Unchanged warfarin in the plasma was fractionated by normal-phase, high-pressure liquid chromatography, and the enantiomorphic ratios were determined by chemical-ionization mass spectrometry with pentadeuteriowarfarin as the internal standard. A highly significant augmentation of the hypoprothrombinemia of the pseudoracemate occurred during the phenylbutazone regimen (P < 0.001) compared with pseudoracemic warfarin administered alone. There was a highly significant increase in the plasma clearance of dextrowarfarin (P < 0.01) and a significant decrease in the plasma clearance of levowarfarin (P < 0.05) during the phenylbutazone regimen compared with administration of warfarin alone. It was concluded that phenylbutazone augmented the hypoprothrombinemia of pseudoracemic warfarin stereoselectively by inhibiting the metabolic disposition of the more hypoprothrombinemic levowarfarin, yet reduced the plasma levels of pseudoracemic warfarin by greatly augmenting the metabolic disposition of dextrowarfarin.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Aggeler PM, O'Reilly RA, Leong L, Kowitz PE. Potentiation of anticoagulant effect of warfarin by phenylbutazone. N Engl J Med. 1967 Mar 2;276(9):496–501. [PubMed]
  • Lewis RJ, Trager WF, Chan KK, Breckenridge A, Orme M, Roland M, Schary W. Warfarin. Stereochemical aspects of its metabolism and the interaction with phenylbutazone. J Clin Invest. 1974 Jun;53(6):1607–1617. [PMC free article] [PubMed]
  • O'Reilly RA. Interaction of sodium warfarin and disulfiram (antabuse) in man. Ann Intern Med. 1973 Jan;78(1):73–76. [PubMed]
  • O'Reilly RA. Drug interactions involving oral anticoagulants. Cardiovasc Clin. 1974;6(2):23–41. [PubMed]
  • Meinertz T, Gilfrich HJ, Groth U, Jonen HG, Jähnchen E. Interruption of the enterohepatic circulation of phenprocoumon by cholestyramine. Clin Pharmacol Ther. 1977 Jun;21(6):731–735. [PubMed]
  • Aggeler PM, O'Reilly RA. Effect of heptabarbital on the response to bishydroxycoumarin in man. J Lab Clin Med. 1969 Aug;74(2):229–238. [PubMed]
  • Robinson DS, Benjamin DM, McCormack JJ. Interaction of warfarin and nonsystemic gastrointestinal drugs. Clin Pharmacol Ther. 1971 May-Jun;12(3):491–495. [PubMed]
  • Melander A, Wåhlin E. Enhancement of dicoumarol bioavailability by concomitant food intake. Eur J Clin Pharmacol. 1978 Dec 18;14(6):441–444. [PubMed]
  • O'Reilly RA, Nelson E, Levy G. Physicochemical and physiologic factors affecting the absorption of warfarin in man. J Pharm Sci. 1966 Apr;55(4):435–437. [PubMed]
  • Chan KK, Lewis RJ, Trager WF. Absolute configurations of the four warfarin alcohols. J Med Chem. 1972 Dec;15(12):1265–1270. [PubMed]
  • Lewis RJ, Trager WF. The metabolic fate of warfarin: studies on the metabolites in plasma. Ann N Y Acad Sci. 1971 Jul 6;179:205–212. [PubMed]
  • Schary WL, Lewis RJ, Rowland M. Warfarin-phenylbutazone interaction in man: a long term multiple dose study. Res Commun Chem Pathol Pharmacol. 1975 Apr;10(4):663–672. [PubMed]
  • Tillement JP, Zini R, Mattei C, Singlas E. Effect of phenylbutazone on the binding of vitamin K antagonists to albumin. Eur J Clin Pharmacol. 1973 Jun;6(1):15–18. [PubMed]
  • O'Reilly RA, Welling PG, Wagner JG. Pharmacokinetics of warfarin following intravenous administration to man. Thromb Diath Haemorrh. 1971;25(1):178–186. [PubMed]
  • O'Reilly RA, Levy G. Pharmacokinetic analysis of potentiating effect of phenylbutazone on anticoagulant action of warfarin in man. J Pharm Sci. 1970 Sep;59(9):1258–1261. [PubMed]

Articles from The Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation